Kirn D, Venook A, Pena I
Onyx Pharmaceuticals, Richmond, CA 94806, USA.
Transpl Int. 1996;9(5):517-9. doi: 10.1007/BF00336833.
We report a patient with post-transplant lymphoma who was treated by renal allograft nephrectomy, discontinuation of immuno-suppressive therapy, and initiation of acyclovir administration. Despite these measures he appeared to have progressive lymphoma. Had a biopsy and cultures not been done, the diagnosis of aspergillosis would have been missed and the patient might have been treated with chemotherapy, with a potentially lethal outcome. Data from the Cincinnati Transplant Tumor Registry indicate that of 662 patients treated for posttransplant lymphoma, 277 patients died of cancer and 137 died of other causes, of which infection was a major factor. This case emphasizes the importance of proper work-up of patients with apparently progressive lymphomas.
我们报告了一名移植后淋巴瘤患者，该患者接受了同种异体肾移植肾切除术、免疫抑制治疗的中断以及阿昔洛韦给药的起始治疗。尽管采取了这些措施，他的淋巴瘤似乎仍在进展。如果没有进行活检和培养，就会漏诊曲霉病，患者可能会接受化疗，从而可能导致致命的后果。辛辛那提移植肿瘤登记处的数据表明，在662例接受移植后淋巴瘤治疗的患者中，277例死于癌症，137例死于其他原因，其中感染是一个主要因素。该病例强调了对明显进展性淋巴瘤患者进行适当检查的重要性。
